The Motley Fool··Jack DelaneyJ&J Beats Earnings but Faces Patent Cliff Reality Check
Johnson & Johnson exceeded Q1 2026 expectations and raised guidance, though stock declined as Stelara patent losses offset strong drug sales.
JNJdividendgeneric competition